E EXACT SCIENCES CORP
| Market Cap | $20.03B |
| P/E Ratio | — |
| Forward P/E | 55.22 |
| Dividend Yield | — |
| Beta | 1.44 |
| 52W Range | $40.31 - $104.91 |
| # Hedge Funds | 1 |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
Hedge Fund Ownership
| Investor 1 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| Mairs & Power Growth Fund Mairs & Power Inc | 0.02% | $1.75M | 17,236 | Reduce 81.51% |
Insider Trading
| Insider Name of the company insider who made the trade 12 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Herriott JamesSVP, General Counsel & Sec | Sale | 1,000 | $70.00 | $70.00K | 19 Nov 2025 | 21 Nov 2025 |
| ORVILLE JACOB AEVP, GM, Screening | Sale | 5,000 | $75.00 | $375.00K | 19 Nov 2025 | 21 Nov 2025 |
| Jacob A OrvilleEVP, GM, Screening | Sale | 5,000 | $75.00 | $375.00K | 19 Nov 2025 | 21 Nov 2025 |
| James HerriottSVP, General Counsel & Sec | Sale | 1,000 | $70.00 | $70.00K | 19 Nov 2025 | 21 Nov 2025 |
| Baranick BrianEVP, GM, Precision Oncology | Sale | 2,858 | $70.08 | $200.29K | 04 Nov 2025 | 06 Nov 2025 |
| Herriott JamesSVP, General Counsel & Sec | Sale | 1,500 | $70.08 | $105.12K | 04 Nov 2025 | 06 Nov 2025 |
| James HerriottSVP, General Counsel & Sec | Sale | 1,500 | $70.08 | $105.12K | 04 Nov 2025 | 06 Nov 2025 |
| Brian BaranickEVP, GM, Precision Oncology | Sale | 2,858 | $70.08 | $200.29K | 04 Nov 2025 | 06 Nov 2025 |
| Zanotti Katherine S | Sale | 12,000 | $65.00 | $780.00K | 24 Oct 2025 | 27 Oct 2025 |
| Katherine S ZanottiDirector | Sale | 12,000 | $65.00 | $780.00K | 24 Oct 2025 | 27 Oct 2025 |
| Herriott JamesSVP, General Counsel & Sec | Sale | 1,500 | $60.00 | $90.00K | 09 Oct 2025 | 10 Oct 2025 |
| Doyle James Edward | Sale | 2,000 | $60.00 | $120.00K | 09 Oct 2025 | 10 Oct 2025 |
Frequently Asked Questions
What is EXAS stock price today?
EXACT SCIENCES CORP (EXAS) is currently trading at $104.91. The stock has a 52-week range of $40.31 to $104.91 and a market capitalization of $20.03B.
Is EXAS a good stock to buy in 2026?
EXACT SCIENCES CORP has a P/E ratio of N/A (forward P/E: 55.2), a dividend yield of none, and 1-year performance of +136.9%. 1 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling EXAS stock?
There have been 12 insider transactions for EXAS in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has EXAS stock performed over the past year?
EXACT SCIENCES CORP (EXAS) has returned +136.9% over the past 12 months. The stock traded between $40.31 and $104.91 during this period, and is currently at $104.91.
Which hedge funds own EXAS (EXACT SCIENCES CORP)?
1 tracked hedge funds currently hold EXAS in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is EXAS's market cap and valuation?
EXACT SCIENCES CORP (EXAS) has a market capitalization of $20.03B. The trailing P/E ratio is N/A and forward P/E is 55.2. The stock is classified in the Healthcare sector.
What is EXAS's revenue and profitability?
EXACT SCIENCES CORP reported revenue of $3.25B with net income of N/A and a profit margin of N/A. The stock has a beta of 1.44.
What sector is EXAS in and who are its biggest institutional holders?
EXACT SCIENCES CORP (EXAS) operates in the Healthcare sector. It is held by 1 tracked hedge funds. See the ownership table above for the complete list.